ERBB2 and breast carcinoma: DESTINY-Breast05 (NCT04622319) is a phase 3 study to evaluate DXd vs. T-DM1 in patients with high-risk HER2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy.